Yves Rinaldi

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab

Anthony Dohan, B. Gallix, Boris Guiu et al. · Gut · 2019 · 135 citations

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial

Christophe Tournigand, Benoist Chibaudel, Benoît Samson et al. · The Lancet Oncology · 2015 · 120 citations

Oncology, Clinical Trials, Colorectal Cancer +8

Bevacizumab+chemotherapy versus chemotherapy alone in elderly patients with untreated metastatic colorectal cancer: a randomized phase II trial—PRODIGE 20 study results

Thomas Aparicio, Olivier Bouché, E. Maillard et al. · Annals of Oncology · 2017 · 76 citations · Full text

Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial

Laëtitia Dahan, Nicolas Williet, Karine Le Malicot et al. · Journal of Clinical Oncology · 2021 · 64 citations

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

Laëtitia Dahan, Jean–Marc Phelip, Karine Le Malicot et al. · Journal of Clinical Oncology · 2018 · 53 citations